These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 16954651)
1. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Kobashi Y; Matsushima T Respiration; 2007; 74(4):394-400. PubMed ID: 16954651 [TBL] [Abstract][Full Text] [Related]
2. [Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy-- following the guidelines for treatment]. Kobashi Y; Oka M Kekkaku; 2008 Dec; 83(12):779-84. PubMed ID: 19172823 [TBL] [Abstract][Full Text] [Related]
3. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Ye JJ; Wu TS; Chiang PC; Lee MH J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Miwa S; Shirai M; Toyoshima M; Shirai T; Yasuda K; Yokomura K; Yamada T; Masuda M; Inui N; Chida K; Suda T; Hayakawa H Ann Am Thorac Soc; 2014 Jan; 11(1):23-9. PubMed ID: 24298907 [TBL] [Abstract][Full Text] [Related]
5. [A study on the effect of combined chemotherapy on Mycobacterium avium complex pulmonary disease]. Sato K; Ebe T Kekkaku; 2000 Jul; 75(7):471-6. PubMed ID: 10944891 [TBL] [Abstract][Full Text] [Related]
6. [Effect of combined chemotherapy following the guidelines on treatment for Mycobacterium avium complex pulmonary disease]. Kobashi Y; Okimoto N; Matsushima T; Shigetou E; Kuraoka T; Takeyama H; Eda R; Yano S; Kobayashi K; Ohnishi T; Mori K; Ueda Y; Moritaka T; Nishimura K; Abe T Kekkaku; 2002 Jun; 77(6):435-41. PubMed ID: 12136597 [TBL] [Abstract][Full Text] [Related]
7. The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease. Kobashi Y; Matsushima T Intern Med; 2003 Aug; 42(8):670-5. PubMed ID: 12924489 [TBL] [Abstract][Full Text] [Related]
8. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Watanabe M; Hasegawa N; Ishizaka A; Asakura K; Izumi Y; Eguchi K; Kawamura M; Horinouchi H; Kobayashi K Ann Thorac Surg; 2006 Jun; 81(6):2026-30. PubMed ID: 16731124 [TBL] [Abstract][Full Text] [Related]
9. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Griffith DE; Brown BA; Cegielski P; Murphy DT; Wallace RJ Clin Infect Dis; 2000 Feb; 30(2):288-92. PubMed ID: 10671330 [TBL] [Abstract][Full Text] [Related]
10. [Nontuberculous mycobacteriosis; the present status of epidemiology and clinical studies]. Sakatani M Kekkaku; 1999 Apr; 74(4):377-84. PubMed ID: 10355224 [TBL] [Abstract][Full Text] [Related]
11. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Kobashi Y; Matsushima T; Oka M Respir Med; 2007 Jan; 101(1):130-8. PubMed ID: 16750618 [TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. Kadota JI; Kurashima A; Suzuki K J Infect Chemother; 2017 May; 23(5):293-300. PubMed ID: 28254517 [TBL] [Abstract][Full Text] [Related]
13. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Jenkins PA; Campbell IA; Banks J; Gelder CM; Prescott RJ; Smith AP Thorax; 2008 Jul; 63(7):627-34. PubMed ID: 18250184 [TBL] [Abstract][Full Text] [Related]
14. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report. Ige OM; Bakare NA; Onadeko BO Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469 [TBL] [Abstract][Full Text] [Related]
16. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. Kobashi Y; Abe M; Mouri K; Obase Y; Kato S; Oka M J Infect Chemother; 2012 Aug; 18(4):436-43. PubMed ID: 22205543 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
18. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC; Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516 [TBL] [Abstract][Full Text] [Related]
19. [Perspective of pulmonary MAC infection treatment]. Kurashima A Kekkaku; 2007 Mar; 82(3):195-9. PubMed ID: 17444124 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of non-tuberculous pulmonary mycobacteriosis]. Sakatani M; Nakajima Y Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]